机构:[1]Department of Ultrasound, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,Chengdu, China四川省人民医院四川省肿瘤医院[2]General Surgery Center of PLA, The General Hospital of Western Theater Command, Chengdu, China[3]Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China四川省人民医院[4]Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[5]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[6]Department of Pharmacy, The General Hospital of Western Theater Command, Chengdu, China
Progression of acute pancreatitis (AP) into a severe form usually results in a life-threatening condition with multiple organ dysfunction, and in particular acute lung injury (ALI), often contributes to the majority of AP-associated deaths. Increasing evidence has shown that uncontrolled activation of the immune system with rapid production of inflammatory cytokines play a dominant role in this process. As an intracellular inflammatory signaling platform, the NOD-like receptor protein 3 (NLRP3) inflammasome, is recently reported to be involved in the pathogenesis of AP progression, however, the relationship between NLRP3 inflammasome activation and AP-associated lung injury remains unclear yet. Here, we show that NLRP3 inflammasome activation and subsequent pyroptosis in alveolar macrophages (AMs) is responsible for the lung injury secondary to AP. In addition, plasma-derived exosomes from AP mice is capable of triggering NLRP3-dependent pyroptosis in AMs. Inhibition of exosome release or uptake in vivo by inhibitors substantially suppresses AMs pyroptosis and thereby alleviates AP-induced pulmonary lesion. Collectively, the current work reveals for the first time the involvement of NLRP3dependent pyroptosis induced by plasma exosomes in the pathogenesis of AP-induced ALI, suggesting that the exosome-mediated NLRP3 inflammatory pathway is a potential therapeutic target for the treatment of lung injury during AP.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81570582, 81772001]; Postdoctoral Research Foundation of ChinaChina Postdoctoral Science Foundation [2017M612975]
第一作者机构:[1]Department of Ultrasound, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,Chengdu, China
共同第一作者:
通讯作者:
通讯机构:[3]Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China[4]Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China[5]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China[6]Department of Pharmacy, The General Hospital of Western Theater Command, Chengdu, China[*1]Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.[*2]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
推荐引用方式(GB/T 7714):
Wu Xiao-Bo,Sun Hong-Yu,Luo Zhu-Lin,et al.Plasma-derived exosomes contribute to pancreatitis-associated lung injury by triggering NLRP3-dependent pyroptosis in alveolar macrophages[J].BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE.2020,1866(5):doi:10.1016/j.bbadis.2020.165685.
APA:
Wu, Xiao-Bo,Sun, Hong-Yu,Luo, Zhu-Lin,Cheng, Long,Duan, Xing-Mei&Ren, Jian-Dong.(2020).Plasma-derived exosomes contribute to pancreatitis-associated lung injury by triggering NLRP3-dependent pyroptosis in alveolar macrophages.BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE,1866,(5)
MLA:
Wu, Xiao-Bo,et al."Plasma-derived exosomes contribute to pancreatitis-associated lung injury by triggering NLRP3-dependent pyroptosis in alveolar macrophages".BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1866..5(2020)